EADSF · Airbus SE/ADR
Price & Indicators
Equibles Research
our published analysis of this company-
Research ThesisRocket Lab's $2.2B backlog makes the bull case bigger than Neutron
Rocket Lab's record Q1 and $2.2B backlog show the bull case no longer rests on Neutron alone. The proposed Iridium merger could add a recurring-services engine, while financing, dilution and execution remain the price of that upside.
-
Research ThesisRocket Lab: Backlog is converting, but the $39B market cap is paying for a Neutron debut the company has yet to validate
Rocket Lab enters Q2 2026 with record backlog of $2,219.8M and guided revenue of $225.0M–$240.0M, yet the stock trades at -55.2% from its $150.23 high on a $39.0B market cap against $679.6M of trailing revenue — a gap the equity-funded growth model and the un-flown Neutron debut have to close.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Aerospace & Defense — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EADSF
this stock
Airbus SE/ADR
|
$194.35B | +7.1% | — | — | 0.1% |
|
SPCX
Space Exploration Technologies Corp
|
$1.93T | — | — | — | 1.6% |
|
GE
General Electric Co
|
$382.22B | +19.6% | +18.5% | 43.4 | 1.4% |
|
RTX
RTX Corp
|
$300.23B | +21.6% | +17.1% | 39.2 | 1.3% |
|
BA
Boeing Co
|
$183.11B | +6.7% | +34.5% | 83.3 | 2.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EADSF | +2.5% | +13.6% | +15.8% | +5.7% | +7.1% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +2.1% | +9.2% | +2.0% | +1.8% | -6.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.